Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Hematologic Cancers

43 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Leukemia

    VICCHEM1305

    04/02/2013

    Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

    Basic Science

    Leukemia

    COGAALL08B1

    10/18/2010

    Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

    Basic Science

    Hematologic

    VICCBMT1008

    02/18/2010

    Skin or Gut Infiltrating Foxp3+ Cells and Their Association with Acute Graft-Versus-Host Disease Severity (deidentified)

    Basic Science

    Hematologic

    NMDPBMT0346

    07/09/2003

    Repository for National Donor Program (NMDP) Research Blood Samples.

    Diagnostic

    Leukemia

    ECOGHEMEAI141

    05/10/2016

    Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

    Other

    Hematologic
    Leukemia
    Myelodysplastic Syndrome
    Pediatric Leukemia

    VICCPED1639

    09/28/2016

    Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

    Other

    Lymphoma

    VICCRAD1633

    04/01/2016

    Prospective Observational Trial of Low-Dose Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique

    Other

    Hematologic

    VICCBMT15130

    01/19/2016

    A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

    Other

    Leukemia

    VICCHEM14133

    11/11/2015

    Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

    Other

    Myelodysplastic Syndrome

    VICCBMT1407

    04/17/2015

    A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

    Other

    Multiple Myeloma

    VICCHEM1470

    11/05/2014

    Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)

    Other

    Hematologic

    VICCBMT1401

    08/29/2014

    Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POSTAGE)

    Other

    Hematologic

    VICCBMT1158

    10/20/2011

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications

    Other

    Hematologic

    VICCBMT1110

    11/02/2001

    Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)

    Supportive Care

    Hematologic

    VICCBMT1426

    11/10/2014

    Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

    Treatment

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM1656

    06/06/2017

    A Randomized, Multicenter, Open-Label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination with Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

    Treatment

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM16136

    05/10/2017

    A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Treatment

    Leukemia

    VICCBMT16137

    05/05/2017

    A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

    Treatment

    Leukemia

    VICCHEM16123

    05/03/2017

    A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia

    Treatment

    Hematologic
    Leukemia
    Lymphoma

    VICCBMT1662

    03/10/2017

    A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

    Treatment

    Hematologic

    VICCBMT16110

    03/10/2017

    A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    Myelodysplastic Syndrome

    VICCHEM1622

    03/02/2017

    A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions

    Treatment

    Leukemia
    Lymphoma

    VICCBMT1651

    09/30/2016

    Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

    Treatment

    Hematologic
    Leukemia
    Lymphoma

    VICCBMT1610

    09/30/2016

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM1660

    09/27/2016

    A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

    Treatment

    Leukemia
    Multiple Myeloma

    VICCHEM1621

    09/16/2016

    An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

    Treatment

    Hematologic

    VICCHEM1613

    08/02/2016

    A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction

    Treatment

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    Lymphoma
    Miscellaneous

    VICCPHI1616

    06/08/2016

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

    Treatment

    Leukemia

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Treatment

    Leukemia
    Pediatric Leukemia

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Treatment

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    Leukemia

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Treatment

    Leukemia
    Pediatric Leukemia

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    Multiple Myeloma

    VICCHEM15112

    01/11/2016

    A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

    Treatment

    Multiple Myeloma

    VICCHEM14131

    11/17/2015

    Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

    Treatment

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    Multiple Myeloma

    VICCHEM1437

    09/29/2015

    A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

    Treatment

    Multiple Myeloma

    VICCHEM1526

    07/01/2015

    A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-Refractory to Previous Therapies

    Treatment

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Treatment

    Leukemia

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

    Treatment

    Hodgkin's Lymphoma
    Leukemia, other
    Lymphoid Leukemia
    Multiple Myeloma
    Myeloid and Monocytic Leukemia
    Non-Hodgkin's Lymphoma
    Other Hematopoietic

    VICCNCPED1414

    04/24/2014

    HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus

    Treatment

    Lymphoma

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lymphoma


    Print this page for your doctor